PVLA PALVELLA THERAPEUTICS, INC. Insider Trading

COO Goin sold all 4,302 shares for $547.4K (blended $127.24/share) on 2026-04-15 across 5 separate sales

Chief Operating Officer Kathleen Goin executed 5 separate sales totaling 4,302 shares for $547,398.98, liquidating her entire shareholding at an average price of $127.24 per share on 2026-04-15. The current stock price of $130.01 sits 12.4% below the 52-week high of $148.34, while posting a 30-day gain of +13.8% and 90-day gain of +30.4%, indicating recent strength. The company remains unprofitable with quarterly revenue of $0.00 and net income of $-11,345,000.00, though annual revenue growth reached +65.3% year-over-year. Goin's prior three sales at PVLA on 2026-03-18 all showed positive 30-day outcomes (ranging +9.2% to +10.6%), though 90-day results are not yet measurable for those trades, and her cross-ticker track record shows 3 prior sells with an average 30-day return of +9.9%.

Director Jenkins buys 445 PVLA shares at $112.30; 3 of 3 prior PVLA purchases were well-timed at 90 days.

Jenkins George M, a director at Palvella Therapeutics, purchased 445 shares at $112.30 on March 30, 2026, bringing his holdings to 187.6K shares. His recent trade history at this ticker is notably consistent: three prior open-market buys all showed positive 90-day returns (+23.6%, +22.8%, and +115.5%), demonstrating precise execution timing at this company. However, context is mixed—the stock is currently down 9.2% over 30 days and 18.8% below its 52-week high of $148.34, and Palvella remains unprofitable with negative net income of $-11.3M despite 65.3% annual revenue growth. The timing pattern across Jenkins's prior trades at PVLA suggests precision in entry selection, but the current price action and unprofitability warrant attention to whether this purchase precedes a reversal or further pressure.

COO Kathleen Goin liquidates entire 4,302-share position for $507,610.99 across 3 sales on 2026-03-18

Kathleen Goin, Chief Operating Officer of Palvella Therapeutics, executed three separate sales on March 18, 2026, totaling 4,302 shares for $507,610.99 at an average price of $117.99. The transaction represents a complete exit from her shareholding position, with holdings falling from 4,302 shares to 0 shares post-transaction. This liquidation occurs while the stock trades at $112.50, down 24.2% from its 52-week high of $148.34 but up 41.3% over the prior 30 days. The company reported a net loss of $-11,345,000.00 in the latest period and remains unprofitable despite 65.3% annual revenue growth. The complete divestiture by a C-suite executive warrants examination of whether it reflects operational or financial developments at the company.

PVLA Director Heron purchases 2,400 shares at $125.00 for $300,000.00

Director Elaine J Heron purchased 2,400 shares at $125.00 on 2026-02-27, expanding her holdings from 45,412 to 47,812 shares (a +5.3% increase). The transaction occurred when the stock was trading 10.6% below its 52-week high of $148.34, following a 72.9% surge over the preceding 30 days. However, this purchase should be contextualized against Heron's cross-ticker insider trading track record: across all her open-market transactions, her prior 2 buys averaged -9.1% returns at both 30 and 90 days, with a 0.00% win rate. Palvella itself remains unprofitable with a full-year net income of -$11,345,000.00 and zero quarterly revenue, though the company has demonstrated +65.3% annual revenue growth. The timing and modest 5.3% increase in holdings, combined with the insider's historically poor buy timing across other securities, suggests this transaction warrants observation rather than confidence signaling.

Director Jenkins purchases 4,000 PVLA shares at $125.00 for $500,000; stock now at $132.61, up 72.9% in 30 days.

Director George M. Jenkins purchased 4,000 shares of Palvella Therapeutics at $125.00, bringing his total holdings to 187,171 shares, in a $500,000.00 transaction. The purchase occurs at a notable moment: the stock trades at $132.61, reflecting a 72.9% surge over the past 30 days and a 44.8% gain over 90 days, though it remains 10.6% below its 52-week high of $148.34. Jenkins' prior PVLA transactions show consistently well-timed purchases—three earlier trades at this ticker each delivered positive 90-day returns (ranging from +23.6% to +115.5%), and his cross-ticker track record shows a 100% win rate on his 3 prior buys with an average 90-day return of +54.0%. The company remains unprofitable with a net income of $-11,345,000 in the latest quarter, despite strong annual revenue growth of +65.3%, creating a complex risk-reward backdrop for this accumulation at elevated price levels.

Director Jenkins George M bought 4,990 shares at blended avg $20.20 on 2025-04-09; holdings +58.5% vs pre-transaction.

Jenkins George M, a PVLA director, executed 2 separate purchases on 2025-04-09 totaling 4,990 shares for $100,797.30 at a blended average price of $20.20, increasing his holdings from 8,526 to 13,516 shares (+58.5%). The current price of $19.87 sits 31.5% below the 52-week high and 29.0% below the 30-day average, yet the stock has climbed 42.2% over the past 90 days. Notably, his single prior trade at PVLA (December 18, 2024 buy) delivered a 90-day return of +115.5%, aligning with a 100% win rate in his cross-ticker open-market history. The company remains unprofitable (net income $-2.9M in the latest period) despite 65.3% annual revenue growth, adding context to an insider accumulation at a time of elevated volatility and a material pullback from recent peaks.

Director Jenkins buys 4,000 shares of PVLA at $12.93; stock now trading at $12.00 post-IPO amid unprofitability.

Director George M. Jenkins purchased 4,000 shares at $12.93 on 2024-12-18, just days after PVLA's recent listing (4 trading days old). The stock has already declined to $12.00, placing the purchase $0.93 above current market price. Jenkins holds 180.7K shares post-transaction, a +2.3% increase in his ownership stake. The company is unprofitable (net income of $-2.9M in its most recent full fiscal year) with $0.00 revenue in the latest quarter, though it has demonstrated 65.3% year-over-year revenue growth on a very small base. As a newly listed micro-cap ($15.8M market cap), the stock's volatility and the company's path to profitability remain central questions for investors; an insider buy in the immediate post-IPO window by a director with material holdings warrants monitoring for the signals it may reveal about management's confidence in the near-term trajectory.

Director GERAGHTY buys 1 share of PIRS at $1.00; stock at $17.00, -23.5% from 52-week high.

GERAGHTY purchased a single share at $1.00 on 2024-08-07, establishing an initial position of 1 share. The company is a clinical-stage biotech with zero revenue in the latest quarter and a net loss of $-3.6M, though it posted annual revenue growth of +65.3% year-over-year. The current stock price of $17.00 represents a substantial divergence from the transaction price, suggesting either a significant repricing event post-purchase or data reporting lag. With a market cap of $22.4M and the insider holding just 1 share post-transaction, this purchase amounts to a minimal economic stake and does not indicate material conviction or directional positioning. The transaction warrants review for timing context and rationale, but the trivial share count limits meaningful inference about insider intent.

10% owner ADAR1 Capital purchases 6,000 shares across 3 transactions (Aug 9-12) for $92,325.90; holdings increase 66.2% to 15,067 shares.

ADAR1 Capital Management, a 10% owner, executed 3 separate purchases totaling 6,000 shares for $92,325.90 at prices ranging from $14.89 to $15.88, raising its post-transaction holdings to 15,067 shares from 9,067 shares. The timing coincides with a +132.0% 30-day price surge, placing the blended transaction price of $15.39 well below the current $15.89. However, the company remains unprofitable (annual net income of $-4.9M on revenue of $53.0K quarterly) despite +65.3% annual revenue growth, and the stock trades -54.8% from its 52-week high of $35.12. The substantial increase in this insider's fractional ownership stake, combined with the company's nascent financial profile and extreme recent volatility, merits examination of whether the near-market-rate purchase reflects conviction in fundamentals or opportunistic accumulation amid price recovery.